^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results
Published date:
08/18/2021
Excerpt:
...phase Ia trial of ceritinib + trametinib in patients with ALK- or ROS1-rearranged NSCLC...Six ALK+ patients enrolled at dose level 1, two ALK+ and one ROS1+ patients enrolled at dose level 2....Of nine patients evaluated for best response, two (22%) had partial response (PR) (both in dose level 1), three (33%) had stable disease (SD) (all in dose level 1)...
Trial ID:
